Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

BCGºÐȹ¿¡ ÀÇÇÑ »ýÁã ºñÀå¼¼Æ÷ ¸é¿ªÈ°¼ºµµ ¹× T ¼¼Æ÷ ¾ÆÇüÀÇ º¯È­ Change of Cellular Immunity and T Cell Subset of Mouse Immunocytes Activated by Fractionated Bacillus Calmette-Guerin

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 5È£ p.423 ~ 430
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÀº½Ä/Eunsik Lee Á¤Çö/À±»óÁø/ÀÌÇØ¿ø/¹Î°æÁØ/ÃÖ¿ë°æ/ÀÌÁ¾¿í/Hyeon Jeong/Sang Jin Yoon/Hae Won Lee/Kyung Joor Min/Yong-Kyung Choi/Chongwook Lee

Abstract

¼­·Ð
bacillus Calmette-Guerin(BCG) ¹æ±¤³»ÁÖÀÔ¹ý Àº Morales µîÀÌ Ã³À½À¸·Î ÀÓ»óÀûÀÎ Àû¿ë
À» º¸°íÇÑ ÀÌ·¡ Ç¥À缺 ¹æ±¤¾ÏÀÇ Àç¹ß°ú ÁøÇàÀ» ¸·´Âµ¥ ³Î¸® ÀÌ¿ëµÇ¾î ¿ÔÀ¸¸ç 59%³»Áö
83%ÀÇ Ä¡·áÈ¿°ú¿Í 65%³»Áö 94%ÀÇ ¿¹¹æÀûÀÎ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù MoralesµîÀÌ
ÀÓÀÇÀûÀ¸·Î 120mgÀÇ Pasteur±ÕÁÖ¸¦ ÁÖ 1ȸ 6ÁÖ µ¿¾È ¹æ±¤³»·Î ÁÖÀÔÇÏ¿´À¸¸ç ÀÌ´Â ÇöÀç±îÁö
±âº» °ñ°ÝÀ¸·Î À¯ÁöµÇ¾î ¿Ô´Ù ¹æ±¤³»ÁÖÀÔ¹ý¿¡ »ç¿ëµÇ´Â BCGÀÇ ±ÕÁַδ Tice, Pasteur,
Conn- aught, Glaxo, Moreau, Tokyo µîÀÌ ÀÖ°í Åõ¿©·®Àº ´ë°³107- 10
9
9CFU(colony forming unit)¸¦ ¸ÅÁÖ 1ȸ 6ÁÖ°£ ¹æ±¤³»ÁÖÀÔÇÏ¸ç ±ÕÁÖ¿¡ µû¸¥ Ä¡·á
¼ºÀûÀº Â÷ÀÌ°¡ ¾ø´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
ÀÌó·³ Ç¥À缺 ¹æ±¤¾Ï¿¡ ´ëÇÑ BCG¹æ±¤ÁÖÀÔ¿ä¹ýÀº Å©°Ô ±â´ë¿Í °¢±¤À» ¹Þ°í ÀÖÀ¸³ª ´Ù¾ç
ÇÑ ºÎÀÛ¿ëÀÌ ¹ß»ýµÇ¾î ÀÓ»óÀû Àû¿ë¹üÀ§¸¦ È®´ë½ÃÅ°´Â µ¥ ¹®Á¦Á¡À¸·Î ´ëµÎµÇ°í ÀÖ´Ù Lamm
µîÀº 1278·Ê¿¡ ´ëÇÑ BCGÀÇ ºÎÀÛ¿ëÀ» º¸°íÇÑ ¹Ù¿¡ ÀÇÇϸé ÀüüȯÀÚ Áß 91%¿¡¼­ ¹æ±¤¿°ÀÌ,
3.9%¿¡¼­ °í¿­ÀÌ, 1.3%¿¡¼­ À°¾ÆÁ¾¼º Àü¸³¼±¿°ÀÌ, ±×¸®°í Æó·Å, °üÀý¿°, °£¿°, °üÀýÅë, Ç÷´¢,
¹ßÁø, ºÎ°íȯ¿°, ¹æ±¤¼öÃà µîÀÇ ºÎÀÛ¿ëÀÌ 0.5-1%ÀÇ È¯ÀÚ¿¡¼­ ³ªÅ¸³µ´Ù. º» ¿¬±¸ÀÚµéÀÇ °æÇè
¿¡¼­µµ5¹æ±¤ÀÚ±ØÁõ»óÀÌ 70%¿¡¼­, Ç÷´¢°¡ 40%¿¡¼­, ±×¸®°í 20%¿¡¼­ ´Ù¾çÇÑ Á¤µµÀÇ ¹ß¿­Áõ
»óÀÌ ³ªÅ¸³µ´Ù µû¶ó¼­ ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀ» ÁÙÀÌ·Á´Â ³ë·ÂÀÌ ÇÊ¿äÇÏ´Ù. ºÎÀÛ¿ë¿¡µµ ºÒ±¸ÇÏ°í
BCGÀÇ ¹æ±¤ ³» ÁÖÀÔ ¿ä¹ýÀº ÀÓ»óÀûÀ¸·Î ³Î¸® ÀÌ¿ëµÇ°í ÀÖ´Ù. µû¶ó¼­ Ç×¾Ï È¿°ú´Â ¾ÈÁ¤µÇ³ª
ºÎÀÛ¿ëÀÌ ½ÉÇÑ BCG¿¡¼­ Ç×¾Ï È¿°ú¸¦ ±Ø´ëÈ­½ÃÅ°¸é¼­ ºÎÀÛ¿ëÀÌ ÀûÀ¸¸ç Ç¥ÁØÈ­µÇ°í º¸´Ù Á¤
Á¦µÈ ¸é¿ªÄ¡·áÁ¦¸¦ °³¹ßÇÏ´Â °ÍÀÌ ÇöÀç ÀÓ»ó¿¡¼­ ÇÊ¿äÇÑ ÀÏÀ̶ó ÆÇ´ÜµÇ¸ç º» ¿¬±¸¿¡¼­´Â ÀÌ
¿¡ ´ëÇÑ ±âÃÊ¿¬±¸ÀÇ ÀÏȯÀ¸·Î BCG¸¦ ¼¼Æ÷º® ¼ººÐ°ú ¼¼Æ÷Áú ¼ººÐÀ¸·Î ºÐȹÇÏ¿© ÃßÃâÇÏ°í,
ÀÌ ºÐȹ¹°ÀÇ ¸é¿ª¼¼Æ÷ È°¼ºÈ¿°ú¿Í T ¼¼Æ÷ ¾ÆÇüÀÇ º¯È­¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» °üÂûÇϸç, ºÐȹ¹°°ú
»ì¾ÆÀÖ´Â BCGÀÇ ÀÛ¿ëÀ» ºñ±³ÇÏ¿© Ç×¾Ï ±âÀü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ºÐȹ¹°À» ÆľÇÇÏ°íÀÚ
ÇÑ´Ù.
#ÃÊ·Ï#
Purpose: To develope the bacillus Calmette-Guerin(BCG) antitumor component therapy
which could reduce the adverse effect of intravesical BCG therapy, we investigated the
effect of the fractions of BCG on the immune responses of mouse and compared with
whole BCG.
Materials and Methods: Seven fractions, 4(fraction 1, 2, 3, 4) from BCG cell wall and
1 (fraction 7) front BCG cytoplasm and 2(fraction 5, 6) mixed, were collected by
multiple ultrasonification and centrifugation of BCG solution and the difference of each
fraction was confirmed by spectrophotometric absorbance. Change of lymphokine
killer(LAK), natural killer(NK) and tumor cell dependent cytotoxic(TCDC) activities of
mouse spleen cells were investigated by 51Cr releasing assay and
proportion of T cell subset in mouse spleen and peritoneal lymhocytes were investigated
by flow cytometric analyses using monoclonal antibodies to mouse CD4, CD8 and CD2S
cells.
Results: In LAK and NK activities, fraction 1, 2 and 3 showed similar results with
whole BCG. In TCDC activity, the all 7 fraction showed lower activities compared with
BCG. In T cell subset analyses, similar results were found in fraction 1, 2 and 3
compared with whole BCG.
Conclusions: We could suggest that the antitumor activity of BCG seems to be
mediated by some component in cell wall. Further investigations which could elucidate
these findings should be necessary.
(Korean J Urol 1998; 39: 423¡­30)

Å°¿öµå

Bladder neoplasms; Bacillus Calmette-Guerin; Component therapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS